How Anti-Obesity Drugs are Redefining Pharma and Wellness with David Ricks and Fatima Cody Stanford

Key takeaways

GLP-1 medications represent a revolutionary advancement in the treatment of obesity and other serious health conditions, with ongoing research expanding their potential applications.
Using person-first language is crucial in addressing the stigma around obesity and facilitating a more empathetic healthcare environment.
Access to GLP-1 medications is hindered by systemic issues in the U.S. healthcare system, necessitating reforms to improve affordability and accessibility.
Future studies may reveal even broader uses for GLP-1 medications beyond weight management, potentially treating various addictions and neurological conditions.
Political decisions can significantly affect healthcare regulations, emphasizing the need for constant advocacy for science-based health policies.

Summary

The Revolutionary Impact of GLP-1 Medications

The podcast introduces a significant discussion about GLP-1 medications, specifically drugs like Ozentvic and Manjaro, which have shown potential beyond weight loss, including benefits for conditions like type 2 diabetes, Parkinson's, and even sleep apnea. David Ricks, CEO of Eli Lilly, emphasizes their development journey since 2005 and highlights the broad spectrum of clinical trials underway, underscoring the drugs’ capability to address major health issues.

The Importance of Person-First Language in Obesity Treatment

The dialogue shifts to the stigmatization of obesity and the importance of person-first language. Dr. Fatima Cody Stanford insists on the need for society to recognize 'persons with obesity' rather than labeling individuals as 'obese.' She emphasizes that nearly 75% of Americans are affected by obesity or overweight, which requires a compassionate and nuanced approach to treatment and societal perception.

Access and Affordability of Diabetes and Weight Loss Drugs

A significant concern addressed is the affordability of GLP-1 drugs. Ricks shares insights into the pricing discrepancy between the US and other countries, arguing that the US healthcare system's complexity limits access, emphasizing the need for reform. Both speakers highlight the role of employers and insurers in ensuring patients can obtain these necessary medications, pointing out systemic barriers.

The Broader Applications of GLP-1 Medications

In the latter part of the conversation, the potential future applications of GLP-1 medications beyond obesity and diabetes are explored. The discussion raises the intriguing notion of these drugs being effective for conditions like alcohol use disorder and Alzheimer's, suggesting a transformative breakthrough in medicine, while also addressing the accompanying risks like muscle loss and gastrointestinal side effects.

Concerns Over Health Regulations

The podcast concludes with a reflection on the potential impact of political changes on health regulations, specifically addressing the possibility of RFK, Jr. stepping into a regulatory role. This part underscores the importance of maintaining rigorous scientific standards in medication approval and the overall message of valuing patient health.

Show notes

Two of the leading experts on anti-obesity drugs say the drugs are heralding a new era in medicine and could soon be used to treat a raft of other conditions.

David Ricks, the chair and chief executive of Eli Lilly, and Dr. Fatima Cody Stanford, obesity medicine physician at Massachusetts General Hospital/Harvard Medical School, talk through the groundbreaking role of GLP-1 medications in transforming the treatment of obesity, and how the drug could potentially be used to treat alcohol use disorder or other addictions.

This interview was with Andrew Ross Sorkin of The New York Times at the annual DealBook Summit and recorded live in front of an audience at Jazz at Lincoln Center. Read more about highlights from the day at https://www.nytimes.com/live/2024/12/04/business/dealbook-summit-news

Subscribe today at nytimes.com/podcasts or on Apple Podcasts, Spotify and Amazon Music. You can also subscribe via your favorite podcast app here https://www.nytimes.com/activate-access/audio?source=podcatcher. For more podcasts and narrated articles, download The New York Times app at nytimes.com/app.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.